CVS paid $315M over unlawful opioid prescriptions billed to federal healthcare programs

CVS Pharmacy Inc. and its related corporate entities agreed to pay $315 million to resolve allegations that, from October 17, 2013 through December 2, 2025, they illegally filled prescriptions for opioids and other controlled substances in violation of the Controlled Substances Act, then sought payment for many of them from Medicare and other federal healthcare programs in violation of the False Claims Act. The Justice Department announced the settlement on October 13, 2026.

The government's complaint, filed December 13, 2024 in the District of Rhode Island, alleged CVS knowingly dispensed prescriptions lacking a legitimate medical purpose: dangerous and excessive opioid quantities, prescriptions filled too early, and 'trinity' prescriptions — an abused opioid-benzodiazepine-muscle relaxant combination. CVS also allegedly filled prescriptions from 'pill mill' prescribers who issued large numbers of controlled-substance prescriptions without any medical purpose, despite clear red flags, and many were billed to and reimbursed by federal healthcare programs.

The complaint further alleged the violations stemmed from corporate-imposed performance metrics, incentive compensation and staffing policies that prioritized profits over patient safety: CVS failed to employ enough pharmacists, and its policies prevented pharmacists from warning one another about problematic prescribers. The settlement resolves a whistleblower suit by former CVS employee Hillary Estright under the FCA's qui tam provision (United States ex rel. Estright v. CVS Health Corporation, No. 22-cv-00222, D.R.I.), in which the United States intervened.

Beyond the payment, CVS entered a memorandum of agreement with the DEA requiring it to establish a hotline for employees and the public to report suspected illegal dispensing, proactively monitor dispensing patterns across its pharmacies, and set up a process to evaluate prescribers suspected of illegal prescribing. The Justice Department noted the claims resolved by the settlement are allegations only, with no determination of liability.

$315M settlement; DEA memorandum requiring a reporting hotline, dispensing-pattern monitoring and prescriber evaluations

It filled prescriptions lacking a legitimate medical purpose — excessive opioid quantities, refills too early, and abused 'trinity' combinations.

It filled prescriptions from 'pill mill' prescribers despite clear red flags that they were invalid.

Corporate performance metrics, incentive compensation and understaffing prioritized speed and profit over pharmacists' compliance obligations.

Its policies prevented pharmacists from warning one another about problematic prescribers.

It sought federal reimbursement for many of the invalid prescriptions, adding False Claims Act exposure on top of the CSA violations.

Performance metrics reach the counter: when corporate targets squeeze staffing, the safety check that gets skipped is the pharmacist's own red-flag judgment.

Under the October 13, 2026 settlement CVS pays $315 million and must implement the DEA memorandum's safeguards, including proactive monitoring of opioid dispensing patterns. The whistleblower's share of the recovery has not been determined. The settlement was announced as a milestone in the Justice Department's crackdown on pharmacies that unlawfully dispense controlled substances.